H. pylori eradication does not reduce gastric cancer incidence in a high-risk area of China - 24/08/11
Abstract |
Question |
Does treating H. Pylori reduce the incidence of gastric cancer?
Study |
Randomised placebo-controlled trial.
Main results |
At 7.5 years, incidence of gastric cancer was not significantly different between groups (treatment: 0.86%, n=7; placebo: 1.35%, n=11; p=0.33). In people without precancerous lesions at baseline, risk of gastric cancer was significantly lower for treatment compared with placebo (incidence of gastric cancer: treatment n=0; placebo n=6; p=0.02) but there was no difference among people with precancerous lesions (n=7 and 5, respectively). Smoking (hazard ratio [HR] 6.2, 95% CI 2.3 to 16.5) and older age (HR per 1 year 1.10, 95% CI 1.05 to 1.15) were independent predictors of gastric cancer risk.
Authors’ conclusions |
Incidence of gastric cancer was similar between H. pylori eradication and placebo groups over 7.5 years of follow-up. However, it was significantly reduced in a subgroup of people without precancerous lesions at baseline.
Le texte complet de cet article est disponible en PDF.Keywords : Gastric cancer, Helicobacter pylori, Prevention, China, Randomised controlled trial
Plan
 | Abstracted from: Wong BCY, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. A randomized controlled trial. JAMA 2004; 291: 187–194. |
Vol 8 - N° 4
P. 218-220 - août 2004 Retour au numéro
Article précédent
- Consuming less than 4 alcoholic drinks per week does not increase risk of pre-term delivery
- Heather L. Paladine
- Liver cancer screening in a high-risk population in China fails to reduce mortality
- Sammy Saab
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?